The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 4+ companies and 4+ ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

Pfizer offers a 6.7% dividend yield, trading at a low valuation with resilient drug portfolio growth. Realty Income Corp. has ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Amid rising risks, I favor high-yield stocks with strong business models. Check out the stock picks that offer stability, ...

Realty Income has a solid strategy. It largely caters to companies in non-discretionary, service-oriented, non-retail, and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, ...

CEO Albert Bourla says that the company has added about $20 billion thus far, with its acquisition of oncology company Seagen in 2023 contributing a big piece of that sum. While another big deal ...

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone as a second-line ...